N-Acetyl Cysteine in the Treatment of Obsessive Compulsive and Related Disorders: A Systematic Review

다국어 초록 (Multilingual Abstract)

Objective: Obsessive compulsive and related disorders are a collection of debilitating psychiatric disorders in which the role of glutamate dysfunction in the underpinning neurobiology is becoming well established. N-acetyl cysteine (NAC) is a glutamate modulator with promising therapeutic effect. This paper presents a systematic review of clinical trials and case reports exploring the use of NAC for these disorders. A further objective was to detail the methodology of current clinical trials being conducted in the area.
Methods: PubMed, Web of Science and Cochrane Library Database were searched for human clinical trials or case reports investigating NAC in the treatment of obsessive compulsive disorder (OCD) or obsessive compulsive related disorders.
Researchers with known involvement in NAC studies were contacted for any unpublished data.
Results: Four clinical trials and five case reports/series were identified. Study durations were commonly 12-weeks, using 2,400-3,000 mg/day of NAC. Overall, NAC demonstrates activity in reducing the severity of symptoms, with a good tolerability profile and minimal adverse effects. Currently there are three ongoing randomized controlled trials using NAC for OCD (two adults and one pediatric), and one for excoriation.
Conclusion: Encouraging results have been demonstrated from the few pilot studies that have been conducted. These results are detailed, in addition to a discussion of future potential research.

참고문헌 (Reference)

1 Adler CM., "fMRI of neuronal activation with symptom provocation in unmedicated patients with obsessive compulsive disorder" 34 : 317-324, 2000

2 Piras F, "Widespread structural brain changes in OCD: A systematic review of voxel-based morphometry studies" 2013

3 Stein DJ., "Trichotillomania(hair pulling disorder), skin picking disorder, and stereotypic movement disorder : toward DSM-V" 27 : 611-626, 2010

4 Franklin ME., "Treatment of obsessive compulsive disorder" 7 : 229-243, 2011

5 Smith QR., "Transport of glutamate and other amino acids at the blood-brain barrier" 130 (130): 1016S-1022S, 2000

6 Bonanomi L., "Toxicological, pharmacokinetic and metabolic studies on acetylcysteine" 111 : 45-51, 1980

7 Papakostas GI., "Tolerability of modern antidepressants" 69 (69): 8-13, 2008

8 Wu K., "The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder" 100 : 726-735, 2012

9 Berk M., "The promise of N-acetylcysteine in neuropsychiatry" 34 : 167-177, 2013

10 Chamberlain SR., "The neuropsychology of obsessive compulsive disorder : the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers" 29 : 399-419, 2005

11 Bandelow B., "The medical treatment of obsessive- compulsive disorder and anxiety" 13 (13): 37-46, 2008

12 Kalivas PW., "The glutamate homeostasis hypothesis of addiction" 10 : 561-572, 2009

13 Ruscio AM., "The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication" 15 : 53-63, 2010

14 Berk M., "The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression : an open label trial" 135 : 389-394, 2011

15 Kupchik YM., "The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine" 71 : 978-986, 2012

16 Swedo SE., "Streptococcal infection, Tourette syndrome, and OCD: is there a connection? PANDAS: horse or zebra?" 74 : 1397-1398, 2010

17 Stein DJ., "Should OCD be classified as an anxiety disorder in DSM-V?" 27 : 495-506, 2010

18 Ozdemir E., "Serum selenium and plasma malondialdehyde levels and antioxidant enzyme activities in patients with obsessivecompulsive disorder" 33 : 62-65, 2009

19 Goddard AW., "Serotoninergic mechanisms in the treatment of obsessivecompulsive disorder" 13 : 325-332, 2008

20 Ahmari SE., "Repeated cortico-striatal stimulation generates persistent OCD-like behavior" 340 : 1234-1239, 2013

21 Behl A., "Relationship of possible stress-related biochemical markers to oxidative/antioxidative status in obsessive-compulsive disorder" 61 : 210-214, 2010

22 Clarke DJ., "Prader-Willi syndrome, compulsive and ritualistic behaviours : the first population-based survey" 180 : 358-362, 2002

23 Fontenelle LF., "Obsessive-compulsive disorder, impulse control disorders and drug addiction : common features and potential treatments" 71 : 827-840, 2011

24 Milad MR., "Obsessive-compulsive disorder : beyond segregated cortico-striatal pathways" 16 : 43-51, 2012

25 Camfield DA., "Nutraceuticals in the treatment of obsessive compulsive disorder(OCD) : a review of mechanistic and clinical evidence" 35 : 887-895, 2011

26 Riaza Bermudo-Soriano C., "New perspectives in glutamate and anxiety" 100 : 752-774, 2012

27 Ting JT., "Neurobiology of obsessive-compulsive disorder : insights into neural circuitry dysfunction through mouse genetics" 21 : 842-848, 2011

28 Berk M., "Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting" 14 : 357-360, 2009

29 Grant JE., "N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania : a double-blind, placebo-controlled study" 66 : 756-763, 2009

30 Gray KM., "N-acetylcysteine(NAC)in young marijuana users : an open-label pilot study" 19 : 187-189, 2010

31 Ghanizadeh A., "N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial" 12 : 223-228, 2013

32 De Rosa SC., "N-acetylcysteine replenishes glutathione in HIV infection" 30 : 915-929, 2000

33 Schmaal L., "N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients : a randomized crossover magnetic resonance spectroscopy study" 37 : 2143-2152, 2012

34 Rodrigues-Barata AR., "N-acetylcysteine in the treatment of trichotillomania" 4 : 176-178, 2012

35 Silva-Netto R., "N-acetylcysteine in the treatment of skin-picking disorder" 36 : 101-, 2014

36 Van Ameringen M., "N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder : A case series" 2 : 48-52, 2013

37 Lafleur DL., "N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder" 184 : 254-256, 2006

38 Afshar H., "N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder : a randomized, double-blind, placebo-controlled trial" 32 : 797-803, 2012

39 Egashira N., "N-acetyl-L-cysteine inhibits marble-burying behavior in mice" 119 : 97-101, 2012

40 Baker DA., "N-acetyl cysteine-induced blockade of cocaineinduced reinstatement" 1003 : 349-351, 2003

41 Grant JE., "N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling : a pilot study" 62 : 652-657, 2007

42 Dean OM., "N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats : relevance to schizophrenia and bipolar disorder" 499 : 149-153, 2011

43 Odlaug BL., "N-acetyl cysteine in the treatment of grooming disorders" 27 : 227-229, 2007

44 Berk M., "N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial" 64 : 468-475, 2008

45 Atkuri KR., "N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency" 7 : 355-359, 2007

46 Bloch MH., "N-Acetylcysteine in the treatment of pediatric trichotillomania : a randomized, double-blind, placebo-controlled add-on trial" 52 : 231-240, 2013

47 Chamberlain SR., "Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania" 163 : 1282-1284, 2006

48 Das P., "Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo" 47 : 347-354, 2013

49 Sheffner AL., "Metabolic studies with acetylcysteine" 15 : 1523-1535, 1966

50 Bloch MH., "Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder" 15 : 850-855, 2010

51 Chamberlain SR., "Lifting the veil on trichotillomania" 164 : 568-574, 2007

52 Costa-Campos L., "Interactive effects of N-acetylcysteine and antidepressants" 44 : 125-130, 2013

53 Menzies L., "Integrating evidence from neuroimaging and neuropsychological studies of obsessivecompulsive disorder : the orbitofronto-striatal model revisited" 32 : 525-549, 2008

54 Erickson MA., "Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier : protection by the antioxidant N-acetylcysteine" 26 : 1085-1094, 2012

55 Flessner CA., "Hair pulling disorder(trichotillomania) : genes, neurobiology, and a model for understanding impulsivity and compulsivity" 199 : 151-158, 2012

56 Lavoie S., "Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients" 33 : 2187-2199, 2008

57 Lushchak VI., "Glutathione homeostasis and functions : potential targets for medical interventions" 2012 : 736837-, 2012

58 Chakrabarty K., "Glutamatergic dysfunction in OCD" 30 : 1735-1740, 2005

59 Arnold PD., "Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder" 63 : 769-776, 2006

60 Grados MA., "Glutamate drugs and pharmacogenetics of OCD : a pathway-based exploratory approach" 8 : 1515-1527, 2013

61 Pittenger C., "Glutamate abnormalities in obsessive compulsive disorder : neurobiology, pathophysiology, and treatment" 132 : 314-332, 2011

62 Ersan S., "Examination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorder" 30 : 1039-1042, 2006

63 Pallanti S., "Emerging drugs to treat obsessive-compulsive disorder" 19 : 67-77, 2014

64 Burdo J., "Distribution of the cystine/glutamate antiporter system xc-in the brain, kidney, and duodenum" 54 : 549-557, 2006

65 Arfsten DP., "Distribution of radio-labeled N-Acetyl-L-Cysteine in Sprague-Dawley rats and its effect on glutathione metabolism following single and repeat dosing by oral gavage" 26 : 113-134, 2007

66 Baker DA., "Cystine/glutamate exchange serves as the source for extracellular glutamate : modifications by repeated cocaine administration" 23 : 161-162, 2002

67 Moran MM., "Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking" 25 : 6389-6393, 2005

68 Bauer J., "Craving in alcohol-dependent patients after detoxification is related to glutamatergic dysfunction in the nucleus accumbens and the anterior cingulate cortex" 38 : 1401-1408, 2013

69 Chakraborty S., "Correlation between lipid peroxidation-induced TBARS level and disease severity in obsessive-compulsive disorder" 33 : 363-366, 2009

70 Sarris J., "Complementary medicine, self-help, and lifestyle interventions for obsessive compulsive disorder(OCD)and the OCD spectrum : a systematic review" 138 : 213-221, 2012

71 Harrison BJ., "Brain corticostriatal systems and the major clinical symptom dimensions of obsessive-compulsive disorder" 73 : 321-328, 2013

72 Kau KS., "Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes cocaine-induced drug seeking" 155 : 530-537, 2008

73 Bulut M., "Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia" 10 : 626-628, 2009

74 Dickel DE., "Association testing of the positional and functional candidate gene SLC1A1/ EAAC1 in early-onset obsessive-compulsive disorder" 63 : 778-785, 2006

75 Bhattacharyya S., "Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder" 34 : 2489-2496, 2009

76 Yücel M., "Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessivecompulsive disorder" 42 : 467-477, 2008

77 Miller JL., "An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome" 164A : 421-424, 2014

78 Panza KE., "Age and gender correlates of pulling in pediatric trichotillomania" 52 : 241-249, 2013

79 Hardan AY., "A randomized controlled pilot trial of oral N-acetylcysteine in children with autism" 71 : 956-961, 2012

80 Morgan JR., "A preliminary analysis of the phenomenology of skin-picking in Prader-Willi syndrome" 41 : 448-463, 2010

81 Chamberlain SR., "A neuropsychological comparison of obsessive-compulsive disorder and trichotillomania" 45 : 654-662, 2007

82 Brennan BP., "A critical review of magnetic resonance spectroscopy studies of obsessivecompulsive disorder" 73 : 24-31, 2013

83 Slade T., "2007 National Survey of Mental Health and Wellbeing : methods and key findings" 43 : 594-605, 2009